[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371817-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371817-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","molecular-landscape-and-treatment-paradigms-of-hepatocellular-and-cholangiocarcinoma-a-multinational-review","Molecular Landscape and Treatment Paradigms of Hepatocellular and Cholangiocarcinoma - A Multinational Review","","Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are the most prevalent primary liver cancers and remain major oncology challenges. A multinational review synthesizes current knowledge of the molecular landscape underlying HCC and CCA pathogenesis, focusing on key pathways and therapy-relevant, actionable targets. Advances in molecular diagnostics are shown to reshape treatment paradigms through precision oncology, including emerging diagnostic standards and streamlined workflows. The review highlights vascular endothelial growth factor, immune checkpoint and tyrosine kinase targeting in HCC, and FGFR2 fusions and IDH1 mutations driving targeted therapy development in CCA, while emphasizing multidisciplinary collaboration.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/molecular-landscape-and-treatment-paradigms-of-hepatocellular-and-cholangiocarcinoma-a-multinational-review/371817/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/molecular-landscape-and-treatment-paradigms-of-hepatocellular-and-cholangiocarcinoma-a-multinational-review/371817.png","ImageObject",300,407,{"name":42,"@type":43},"4398046744996","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What do HCC and CCA represent, and why are they challenging in oncology?","Question",{"text":63,"@type":64},"Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are the most prevalent primary liver cancers and pose significant challenges in oncology due to clinically important complexity and variability worldwide.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does molecular diagnostics influence treatment paradigms for HCC and CCA?",{"text":68,"@type":64},"Recent advances in molecular diagnostics reshape treatment strategies for both cancers by enabling identification of molecular pathways and actionable targets that support precision medicine.",{"name":70,"@type":61,"acceptedAnswer":71},"Which actionable targets and genetic alterations are emphasized for HCC versus CCA?",{"text":72,"@type":64},"For HCC, therapeutic potential is highlighted for targeting VEGF, immune checkpoints, and tyrosine kinase pathways. For CCA, actionable genetic alterations such as FGFR2 fusions and IDH1 mutations are presented as drivers for targeted therapies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371817,1790387185,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":11,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":138,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":113,"preview_page_count":33,"preview_urls":144},4398046744996,"Article published online: 2025-03-31  \nÜbersicht  \nMolecular Landscape and Treatment Paradigms of Hepatocellular and Cholangiocarcinoma: A Multinational Review  \nMolekulare Landschaft und Therapieparadigmen  \nbei hepatozellulärem Karzinom und Cholangiokarzinom: Eine multinationale Übersichtsarbeit  \nAuthors  \nKristijan Skok1, 2, Judith Stift3, 4, Peter Schirmacher5, Karl Kashofer1, Rudolf Stauber6, Branislava Ranković7, Karoline Lackner1, 4  \nAffiliations  \n1 Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria  \n2 Insitute of Biomedical Sciences, Faculty of Medicine University of Maribor in Slovenia, Maribor, Slovenia  \n3 Institute of Pathology, Versorgungspathologie of the University Clinic of Innsbruck, INNPATH GmbH, Innsbruck, Austria  \n4 ADK Diagnostics, Center for Liver and Pancreatic Pathology, Vienna, Austria  \n5 Heidelberg University Hospital Institute of Pathology, Heidelberg, Germany  \n6 Internal Medicine, Medical University of Graz, Graz, Austria  \n7 Institute of Pathology, University of Ljubljana Faculty of Medicine, Ljubljana, Slovenia  \nKeywords  \nHepatocellular Carcinoma, Cholangiocarcinoma, Molecular Targeted Therapy, Precision Medicine, Molecular Diagnostics  \nSchlüsselwörter  \nHepatozelluläres Karzinom, Cholangiokarzinom, Präzisionsmedizin, Molekulare Diagnostik, Zielgerichtete Therapie  \nreceived 21.1.2025  \naccepted after revision 24.2.2025 published online 31.3.2025  \nBibliography  \nZ Gastroenterol 2025; 63: 948–959  \nDOI 10.1055/a-2548-0108 ISSN 0044-2771  \n© 2025. The Author(s) .  \nThis is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/4.0/](creativecommons.org/licenses/by/4.0/)).  \nGeorg Thieme Verlag KG, Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany  \nCorrespondence  \nKristijan Skok, MD, PhD  \nDiagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria [kristijan.skok@medunigraz.at](kristijan.skok@medunigraz.at)  \nProf. Dr. Karoline Lackner  \nDiagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria  \n[karoline.lackner@medunigraz.at](karoline.lackner@medunigraz.at)[ ](karoline.lackner@medunigraz.at)ABSTRACT  \nHepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) represent the most prevalent primary liver cancers and pose significant challenges in oncology. While their etiology and incidence vary globally, the molecular landscape of these tumors is increasingly understood, offering new opportunities for precision medicine. In this joint multinational review, we present a comprehensive analysis of the key molecular pathways involved in the pathogenesis of HCC and CCA, highlighting actionable targets for emerging therapies. Recent advances in molecular diagnostics have significantly influenced treatment paradigms for both cancers. In HCC, while genetic alterations have not yet led to established diagnostic or therapeutic applications, targeting vascular endothelial growth factor (VEGF), immune checkpoints, and tyrosine kinase pathways has demonstrated considerable therapeutic potential. In CCA, genetic profiling has uncovered actionable alterations, such as FGFR2 fusions and IDH1 mutations, driving the development of targeted therapies. The growing complexity of precision oncology underscores the need for standardized molecular testing and streamlined diagnostic workflows to ensure timely and effective treatment. This review also emphasizes the importance of collaborative efforts between clinicians, pathologists, and oncologists to optimize outcomes . By synthesizing the latest molecular insights and treatment trends, this review provides a valuable resource to guide the personalized management of HCC and CCA.  \n948 Skok K et al. Molecular Landscape and… Z Gastroenterol ","cbCaidwOo7TCJrGr","https://ap.wps.com/l/cbCaidwOo7TCJrGr","pdf",970433,12,"English","# Abstract\n# Introduction\n## Molecular landscape and precision medicine\n## Treatment paradigms for HCC and CCA","[{\"question\":\"What do HCC and CCA represent, and why are they challenging in oncology?\",\"answer\":\"Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are the most prevalent primary liver cancers and pose significant challenges in oncology due to clinically important complexity and variability worldwide.\"},{\"question\":\"How does molecular diagnostics influence treatment paradigms for HCC and CCA?\",\"answer\":\"Recent advances in molecular diagnostics reshape treatment strategies for both cancers by enabling identification of molecular pathways and actionable targets that support precision medicine.\"},{\"question\":\"Which actionable targets and genetic alterations are emphasized for HCC versus CCA?\",\"answer\":\"For HCC, therapeutic potential is highlighted for targeting VEGF, immune checkpoints, and tyrosine kinase pathways. For CCA, actionable genetic alterations such as FGFR2 fusions and IDH1 mutations are presented as drivers for targeted therapies.\"}]","Molecular Landscape and Treatment Paradigms of Hepatocellular and Cholangiocarcinoma - A Multinational Review | PDF",1790192937,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d587143a049211d719cd6e1678a002da.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e3eedc1bf548173bfa2e8386fe1f277.webp",982,1309,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/adfbb629fc0e0f34e2332c2c09f8c5e5.webp",981,1308,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6890fd848d2dbe66fa141fcbb767dbe.webp",980,1306]